ProQR Therapeutics N.V. (PRQR) stock
Close on Nov 13, 2026Market cap $148.56MP/E –Yield –
ProQR Therapeutics N.V. grew revenue 11.4% to €18.36M over the twelve months to Jun 30, 2026. Free cash flow was -€50.16M. At the latest close the market valued the company at €133.19M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- €133.19M
- P/E ratio
- –
- Price to sales
- 7.25
- Price to book
- 1.68
- Dividend yield
- –
- Free cash flow yield
- -37.66%
Fundamentals
- Revenue
- €18.36M
- Net income
- -€42.04M
- EPS, diluted
- -0.39 EUR
- Free cash flow
- -€50.16M
- Book value per share
- 0.72 EUR
- Diluted shares
- 110M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.36
- Open
- $1.39
- Day's range
- $1.37 – $1.44
- Volume
- 568,640
- Average volume (20 days)
- 782,758
- Beta (5 years)
- 1.26
- RSI (14 days)
- 49.0
- Volatility (1 year)
- 74.8%
- Relative volume
- 0.69×
- WACC
- 11.2%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | PRQR | S&P 500 | Difference | PRQR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.7% | -3.0% | −1.7 pts | ||
| 3 months | -23.8% | -2.8% | −21.0 pts | ||
| Year to date | -30.2% | +11.5% | −41.7 pts | ||
| 1 year | -34.7% | +13.5% | −48.2 pts | ||
| 3 years | +0.7% | +77.7% | −77.0 pts | +0.2% | +21.1% |
| 5 years | -81.9% | +72.6% | −154.5 pts | -29.0% | +11.5% |
| 10 years | -70.6% | +308.2% | −378.8 pts | -11.5% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, EUR
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ProQR Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About ProQR Therapeutics
Pharmaceutical Preparations
ProQR Therapeutics N.V. is a biopharmaceutical company that discovers and develops therapies using an RNA editing technology platform. The company focuses on advancing preclinical and clinical development programs, including investigational RNA-targeted product candidates such as ultevursen and sepofarsen. Rather than selling commercial treatments directly to end users, ProQR works in collaboration with global pharmaceutical companies, research organizations, and patient foundations. Its partners include Eli Lilly and Company, the Rett Syndrome Research Trust, and the Foundation Fighting Blindness.
Company profile, executives and historyProQR Therapeutics stock: common questions
What is ProQR Therapeutics's stock price?
PRQR closed at $1.41 on Nov 13, 2026, up 3.68% on the day.
What is ProQR Therapeutics's market cap?
ProQR Therapeutics was worth $148.56M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is PRQR's P/E ratio?
ProQR Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -0.39 EUR), so it has no meaningful P/E ratio.
How much revenue does ProQR Therapeutics make?
ProQR Therapeutics reported revenue of €18.36M for the twelve months to Jun 30, 2026, up 11.4% from a year earlier.
Does ProQR Therapeutics pay a dividend?
No. ProQR Therapeutics has not paid a cash dividend over the last twelve months.
When does ProQR Therapeutics report earnings next?
ProQR Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has PRQR stock performed over the past year?
Including dividends, PRQR returned -34.7% over the past year, against +13.5% for the S&P 500.
Who are ProQR Therapeutics's competitors?
Companies most similar to ProQR Therapeutics by business, industry and size include NAMS, QURE, CAPR, STOK, PRLD.
See a number that looks wrong?